scholarly journals Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy

2020 ◽  
Vol 4 (19) ◽  
pp. 4798-4801
Author(s):  
Ibrahim Aldoss ◽  
Joo Y. Song ◽  
Peter T. Curtin ◽  
Stephen J. Forman
Keyword(s):  
Transplant Recipient ◽  
Myelodysplastic Syndrome ◽  
Cell Transplantation ◽  
Malignant Transformation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Myeloid Malignancy ◽  
Key Points

Key Points A patient with myelodysplastic syndrome was transplanted twice and developed clonally unrelated relapse each time in donor-derived cells. This case supports the concept that a leukemogenic marrow environment may predispose the transplant recipient to malignant transformation.

scholarly journals Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation

Blood ◽  
2014 ◽  
Vol 124 (16) ◽  
pp. 2596-2606 ◽  
Author(s):  
Joseph Pidala ◽  
Stephanie J. Lee ◽  
Kwang Woo Ahn ◽  
Stephen Spellman ◽  
Hai-Lin Wang ◽  
...  
Keyword(s):  
High Resolution ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Unrelated Donor ◽  
Key Points ◽  
Overall Mortality

Key Points High-resolution matching for HLA-A, -B, -C, and -DRB1 is required for optimal survival in myeloablative-unrelated donor transplantation. HLA-DPB1 nonpermissive mismatches should be avoided in otherwise matched transplants to minimize overall mortality.

scholarly journals Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial

Blood ◽  
2014 ◽  
Vol 124 (1) ◽  
pp. 33-41 ◽  
Author(s):  
Aurélie Jaspers ◽  
Frédéric Baron ◽  
Évelyne Willems ◽  
Laurence Seidel ◽  
Kaoutar Hafraoui ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Prospective Randomized Trial ◽  
Allogeneic Hct ◽  
Transfusion Requirements ◽  
Key Points

Key Points Erythropoietin therapy can be effective to hasten erythroid recovery and reduce transfusion requirements after allogeneic HCT.

Sign in / Sign up

Export Citation Format

Share Document